{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:12:05Z","timestamp":1779297125093,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,22]]},"DOI":"10.7759\/cureus.60850","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:46:01Z","timestamp":1716385561000},"source":"Crossref","is-referenced-by-count":2,"title":["Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Kaoruko","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Sazuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-3060. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors","volume":"36","author":"Iwama S","year":"2021","unstructured":"Iwama S, Kobayashi T, Arima H. Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors. Endocrinol Metab (Seoul). 2021, 36:312-321. 10.3803\/EnM.2021.1007","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-182. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0535","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase","volume":"182","author":"Bai X","year":"2020","unstructured":"Bai X, Chen X, Wu X, Huang Y, Zhuang Y, Lin X. Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase. Eur J Endocrinol. 2020, 182:1-9. 10.1530\/EJE-19-0535","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer PC","year":"2018","unstructured":"Iyer PC, Cabanillas ME, Waguespack SG, et al.. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018, 28:1243-1251. 10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi G","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019, 14:381-398. 10.1080\/17446651.2019.1701434","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer M","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al.. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016, 315:801-810. 10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab022","article-title":"New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays","volume":"5","author":"Javorsky BR","year":"2021","unstructured":"Javorsky BR, Raff H, Carroll TB, Algeciras-Schimnich A, Singh RJ, Col\u00f3n-Franco JM, Findling JW. New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays. J Endocr Soc. 2021, 5:bvab022. 10.1210\/jendso\/bvab022","journal-title":"J Endocr Soc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir CA","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, et al.. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab. 2021, 106:e3704-e3713. 10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment","volume":"23","author":"Patel NS","year":"2018","unstructured":"Patel NS, Oury A, Daniels GA, et al.. Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment. Oncologist. 2018, 23:1236-1241. 10.1634\/theoncologist.2017-0375","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada N","year":"2020","unstructured":"Okada N, Iwama S, Okuji T, et al.. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer. 2020, 122:771-777. 10.1038\/s41416-020-0736-7","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab829","article-title":"Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline","volume":"107","author":"Iwama S","year":"2022","unstructured":"Iwama S, Kobayashi T, Yasuda Y, et al.. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab. 2022, 107:e1620-e1630. 10.1210\/clinem\/dgab829","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al.. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072033","article-title":"Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review","volume":"9","author":"Okura N","year":"2020","unstructured":"Okura N, Asano M, Uchino J, et al.. Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review. J Clin Med. 2020, 9:10.3390\/jcm9072033","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun DJ","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017, 13:195-207. 10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama S","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014, 6:230ra45. 10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje A","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al.. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019, 181:211-219. 10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2020.1817064","article-title":"Primary and ipilimumab-induced hypophysitis: a single-center case series","volume":"45","author":"Atkins P","year":"2020","unstructured":"Atkins P, Ur E. Primary and ipilimumab-induced hypophysitis: a single-center case series. Endocr Res. 2020, 45:246-253. 10.1080\/07435800.2020.1817064","journal-title":"Endocr Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe JR","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. 2016, 4:89. 10.1186\/s40425-016-0196-z","journal-title":"J Immunother Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00693-x","article-title":"Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature","volume":"21","author":"Newman C","year":"2021","unstructured":"Newman C, Kgosidalwa O, Hakami OA, Kennedy C, Grogan L, Agha A. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature. BMC Endocr Disord. 2021, 21:33. 10.1186\/s12902-021-00693-x","journal-title":"BMC Endocr Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993622","article-title":"Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: a case report and review of literature","volume":"13","author":"Hino C","year":"2022","unstructured":"Hino C, Nishino K, Pham B, Jeon WJ, Nguyen M, Cao H. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: a case report and review of literature. Front Immunol. 2022, 13:993622. 10.3389\/fimmu.2022.993622","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036664","article-title":"Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: a case report","volume":"102","author":"Iesaka H","year":"2023","unstructured":"Iesaka H, Kameda H, Miya A, et al.. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: a case report. Medicine (Baltimore). 2023, 102:e36664. 10.1097\/MD.0000000000036664","journal-title":"Medicine (Baltimore)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.k08e-055","article-title":"Clinical characteristics of frequently recurring painless thyroiditis: contributions of higher thyroid hormone levels, younger onset, male gender, presence of thyroid autoantibody and absence of goiter to repeated recurrence","volume":"56","author":"Nishimaki M","year":"2009","unstructured":"Nishimaki M, Isozaki O, Yoshihara A, Okubo Y, Takano K. Clinical characteristics of frequently recurring painless thyroiditis: contributions of higher thyroid hormone levels, younger onset, male gender, presence of thyroid autoantibody and absence of goiter to repeated recurrence. Endocr J. 2009, 56:391-397. 10.1507\/endocrj.k08e-055","journal-title":"Endocr J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.63.GP238","article-title":"Immune checkpoint inhibitors therapy-induced hypophysitis is frequently associated with previous thyroid disorders: results from ImmuCare study","author":"Levy M","year":"2019","unstructured":"Levy M, Abeillon J, Borson-Chazot F, et al.. Immune checkpoint inhibitors therapy-induced hypophysitis is frequently associated with previous thyroid disorders: results from ImmuCare study. Endocr Abstr. 2019, 10.1530\/endoabs.63.GP238","journal-title":"Endocr Abstr"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197918020-00003","article-title":"Alterations of glucocorticoid actions by other drugs and disease states","volume":"18","author":"Jubiz W","year":"1979","unstructured":"Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. Drugs. 1979, 18:113-121. 10.2165\/00003495-197918020-00003","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.60.705.478","article-title":"Addison's disease and thyrotoxicosis presenting simultaneously","volume":"60","author":"Newrick PG","year":"1984","unstructured":"Newrick PG. Addison's disease and thyrotoxicosis presenting simultaneously. Postgrad Med J. 1984, 60:478-479. 10.1136\/pgmj.60.705.478","journal-title":"Postgrad Med J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JM","year":"2019","unstructured":"de Filette JM, Pen JJ, Decoster L, et al.. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-374. 10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey MA","year":"2019","unstructured":"Couey MA, Bell RB, Patel AA, et al.. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019, 7:165. 10.1186\/s40425-019-0645-6","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245970-adrenal-insufficiency-and-thyrotoxicosis-following-combined-immune-checkpoint-inhibitor-use-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:46:04Z","timestamp":1716385564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245970-adrenal-insufficiency-and-thyrotoxicosis-following-combined-immune-checkpoint-inhibitor-use-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.60850","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}